Navigation Links
Akela Pharma receives letter from the FDA regarding its pre-clinical toxicology studies for Fentanyl TAIFUN(R)
Date:2/4/2008

http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL

MONTREAL, Feb. 4 /PRNewswire-FirstCall/ - Akela Pharma Inc. (TSX: "AKL"), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that it has received notice from the FDA that, due to GLP deviations the 6-month inhalation toxicology studies were deemed invalid. No toxicological reasons were cited. We are currently evaluating several alternative remedies and are confident that the submission for regulatory approval will not be delayed by more than 6 months.

Conference call information:

Akela will host a conference call at 9:00 am, on Monday February 4, 2008. Interested parties may also access the conference call by webcast at http://www.akelapharma.com.

The telephone numbers to access the conference call are 1-800-732-9303 or 416-644-3415. A replay of the call will be available until February 11, 2008. The telephone numbers to access the replay are 416-640-1917 and 1-877-289-8525 with code number 21262067#.

About Akela Pharma Inc.:

Akela Pharma is an integrated drug development company focused on developing therapies for the growing multi-billion dollar inhalation and pain markets. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, growth hormone deficiencies and controlled substance abuse deterrent formulations.

Akela's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "AKL" with 11.7 million shares outstanding.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of Akela Pharma Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.


'/>"/>
SOURCE Akela Pharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Akela Pharma provides corporate update
2. Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial
3. Akela Pharma reports results for third quarter of fiscal 2007
4. AKELA Pharma Inc. announces U.S. public offering and proposed listing
5. Akela Pharma Inc. Completes Share Consolidation
6. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
7. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
8. Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of Fourth Quarter Financial Results
9. NxStage Medical to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7, 2008
10. West Hollywood: AHF Hosts Grand Opening of HIV/AIDS Pharmacy that Benefits AIDS Patients Worldwide
11. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... ... Many individuals looking to lead a healthy lifestyle have decreased carbohydrate consumption and ... Fitness has delved into this niche allowing those giving up their beloved pasta a ... 30 grams of protein and only 7 grams of carbohydrates per 50 gram serving--a ...
(Date:2/13/2016)... Salt Lake City, Utah (PRWEB) , ... February 13, 2016 , ... When an ... kids, Host Parents aren’t always sure what they are in for and they are often ... Pairs are more than they were hoping for. This year’s Au Pair of the Year ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, ... Parishes. The purpose of these scholarships is to encourage applicants to pursue a ... seek employment within these two parishes. , “We have available jobs in St. ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Each year, ... will be held in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical ... see new therapy products in action, learn more about their chosen field and network ...
(Date:2/12/2016)... FL (PRWEB) , ... February 12, 2016 , ... ... as a Service (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) ... channel partners to offer real-time business intelligence (BI) to their small and medium ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Feb. 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ... the Company will ring the Nasdaq Closing Bell at ... York at 4:00 p.m. ET on Tuesday, ... Adrian Adams , will perform the ... to 4:00 p.m. ET.  A live webcast will be ...
(Date:2/12/2016)... Ungarn, February 12, 2016 ... sich auf den ungedeckten medizinischen Bedarf bei ... Ergebnisse seines klinischen Forschungsprogramms bekannt. Das Programm, ... ergab Verbesserungen ihrer respiratorischen Funktionen und anderer ... , ein Medizintechnikunternehmen, das sich auf den ...
(Date:2/11/2016)... 11, 2016 Stem cells are primitive cells ... self-renewal and the capacity to differentiate into mature cell ... as the first mouse embryonic stem cells were derived ... 1995 that the first culturing of embryonic stem cells ... not produced until 2006 As a result of these ...
Breaking Medicine Technology: